Double blind clinical trial on centperazine & DEC in bancroftian filariasis.
Identifieur interne : 005D39 ( PubMed/Curation ); précédent : 005D38; suivant : 005D40Double blind clinical trial on centperazine & DEC in bancroftian filariasis.
Auteurs : R N Rath ; B K Das ; M L Ali ; P K Das ; A C Mishra ; B N MohapatraSource :
- The Indian journal of medical research [ 0971-5916 ] ; 1990.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine, Filaricides, Pipérazines.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Humains, Méthode en double aveugle, Wuchereria bancrofti.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Diethylcarbamazine, Filaricides, Piperazines.
- drug effects : Wuchereria bancrofti.
- drug therapy : Elephantiasis, Filarial.
- Adolescent, Adult, Animals, Double-Blind Method, Humans, Middle Aged.
Abstract
Centperazine, an analogue of DEC, was subjected to a double blind controlled trial, to evaluate its efficacy as a newer antifilarial agent. Centperazine (300 mg/day) along with equivalent quantities of DEC and placebo were administered to different types of filariasis patients. DEC was found to be significantly effective in reducing peripheral microfilaraemia, in different weeks and months of follow-up, except at the end of 6th month, as compared to Centperazine. There was no significant difference between the placebo and Centperazine treated patients, in this respect, revealing that the drugs had no efficacy in eliminating peripheral microfilaraemia. Recurrence of acute attack within 6 months was nearly equal with both Centperazine and DEC, being 28.2 and 24 per cent respectively, whereas in the placebo group the recurrence rate was 48.9 per cent. Centperazine treated patients showed significantly less side effects (8.9%), as compared to DEC treated patients (34%). Giddiness, nausea and vomiting were the common adverse effects observed.
PubMed: 2228058
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005D39
Links to Exploration step
pubmed:2228058Curation
No country items
R N Rath<affiliation><nlm:affiliation>Department of Medicine, S.C.B. Medical College.</nlm:affiliation>
<wicri:noCountry code="subField">S.C.B.</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Double blind clinical trial on centperazine & DEC in bancroftian filariasis.</title>
<author><name sortKey="Rath, R N" sort="Rath, R N" uniqKey="Rath R" first="R N" last="Rath">R N Rath</name>
<affiliation><nlm:affiliation>Department of Medicine, S.C.B. Medical College.</nlm:affiliation>
<wicri:noCountry code="subField">S.C.B.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Das, B K" sort="Das, B K" uniqKey="Das B" first="B K" last="Das">B K Das</name>
</author>
<author><name sortKey="Ali, M L" sort="Ali, M L" uniqKey="Ali M" first="M L" last="Ali">M L Ali</name>
</author>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
<author><name sortKey="Mishra, A C" sort="Mishra, A C" uniqKey="Mishra A" first="A C" last="Mishra">A C Mishra</name>
</author>
<author><name sortKey="Mohapatra, B N" sort="Mohapatra, B N" uniqKey="Mohapatra B" first="B N" last="Mohapatra">B N Mohapatra</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1990">1990</date>
<idno type="RBID">pubmed:2228058</idno>
<idno type="pmid">2228058</idno>
<idno type="wicri:Area/PubMed/Corpus">005D39</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005D39</idno>
<idno type="wicri:Area/PubMed/Curation">005D39</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005D39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Double blind clinical trial on centperazine & DEC in bancroftian filariasis.</title>
<author><name sortKey="Rath, R N" sort="Rath, R N" uniqKey="Rath R" first="R N" last="Rath">R N Rath</name>
<affiliation><nlm:affiliation>Department of Medicine, S.C.B. Medical College.</nlm:affiliation>
<wicri:noCountry code="subField">S.C.B.</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Das, B K" sort="Das, B K" uniqKey="Das B" first="B K" last="Das">B K Das</name>
</author>
<author><name sortKey="Ali, M L" sort="Ali, M L" uniqKey="Ali M" first="M L" last="Ali">M L Ali</name>
</author>
<author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P K" last="Das">P K Das</name>
</author>
<author><name sortKey="Mishra, A C" sort="Mishra, A C" uniqKey="Mishra A" first="A C" last="Mishra">A C Mishra</name>
</author>
<author><name sortKey="Mohapatra, B N" sort="Mohapatra, B N" uniqKey="Mohapatra B" first="B N" last="Mohapatra">B N Mohapatra</name>
</author>
</analytic>
<series><title level="j">The Indian journal of medical research</title>
<idno type="ISSN">0971-5916</idno>
<imprint><date when="1990" type="published">1990</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Animals</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Filaricides (therapeutic use)</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Piperazines (therapeutic use)</term>
<term>Wuchereria bancrofti (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Filaricides (usage thérapeutique)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Pipérazines (usage thérapeutique)</term>
<term>Wuchereria bancrofti ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Filaricides</term>
<term>Piperazines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Filaricides</term>
<term>Pipérazines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Animals</term>
<term>Double-Blind Method</term>
<term>Humans</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Humains</term>
<term>Méthode en double aveugle</term>
<term>Wuchereria bancrofti</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Centperazine, an analogue of DEC, was subjected to a double blind controlled trial, to evaluate its efficacy as a newer antifilarial agent. Centperazine (300 mg/day) along with equivalent quantities of DEC and placebo were administered to different types of filariasis patients. DEC was found to be significantly effective in reducing peripheral microfilaraemia, in different weeks and months of follow-up, except at the end of 6th month, as compared to Centperazine. There was no significant difference between the placebo and Centperazine treated patients, in this respect, revealing that the drugs had no efficacy in eliminating peripheral microfilaraemia. Recurrence of acute attack within 6 months was nearly equal with both Centperazine and DEC, being 28.2 and 24 per cent respectively, whereas in the placebo group the recurrence rate was 48.9 per cent. Centperazine treated patients showed significantly less side effects (8.9%), as compared to DEC treated patients (34%). Giddiness, nausea and vomiting were the common adverse effects observed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2228058</PMID>
<DateCreated><Year>1990</Year>
<Month>12</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted><Year>1990</Year>
<Month>12</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0971-5916</ISSN>
<JournalIssue CitedMedium="Print"><Volume>91</Volume>
<PubDate><Year>1990</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>The Indian journal of medical research</Title>
<ISOAbbreviation>Indian J. Med. Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Double blind clinical trial on centperazine & DEC in bancroftian filariasis.</ArticleTitle>
<Pagination><MedlinePgn>277-81</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Centperazine, an analogue of DEC, was subjected to a double blind controlled trial, to evaluate its efficacy as a newer antifilarial agent. Centperazine (300 mg/day) along with equivalent quantities of DEC and placebo were administered to different types of filariasis patients. DEC was found to be significantly effective in reducing peripheral microfilaraemia, in different weeks and months of follow-up, except at the end of 6th month, as compared to Centperazine. There was no significant difference between the placebo and Centperazine treated patients, in this respect, revealing that the drugs had no efficacy in eliminating peripheral microfilaraemia. Recurrence of acute attack within 6 months was nearly equal with both Centperazine and DEC, being 28.2 and 24 per cent respectively, whereas in the placebo group the recurrence rate was 48.9 per cent. Centperazine treated patients showed significantly less side effects (8.9%), as compared to DEC treated patients (34%). Giddiness, nausea and vomiting were the common adverse effects observed.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rath</LastName>
<ForeName>R N</ForeName>
<Initials>RN</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, S.C.B. Medical College.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Das</LastName>
<ForeName>B K</ForeName>
<Initials>BK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ali</LastName>
<ForeName>M L</ForeName>
<Initials>ML</Initials>
</Author>
<Author ValidYN="Y"><LastName>Das</LastName>
<ForeName>P K</ForeName>
<Initials>PK</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mishra</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mohapatra</LastName>
<ForeName>B N</ForeName>
<Initials>BN</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>India</Country>
<MedlineTA>Indian J Med Res</MedlineTA>
<NlmUniqueID>0374701</NlmUniqueID>
<ISSNLinking>0971-5916</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005369">Filaricides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>25143-13-9</RegistryNumber>
<NameOfSubstance UI="C033224">centperazine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>V867Q8X3ZD</RegistryNumber>
<NameOfSubstance UI="D004049">Diethylcarbamazine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004049" MajorTopicYN="N">Diethylcarbamazine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005369" MajorTopicYN="N">Filaricides</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014958" MajorTopicYN="N">Wuchereria bancrofti</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year>
<Month>7</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1990</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1990</Year>
<Month>7</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2228058</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005D39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 005D39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:2228058 |texte= Double blind clinical trial on centperazine & DEC in bancroftian filariasis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:2228058" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |